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Objectives: To analyze the studies encompassing the involvement of pharmacists in
diabetes self-care.
Method: We reviewed studies conducted from 2005 to 2017 on the
involvement of pharmacists in diabetes self-care. The keywords mainly used
in this search are pharmacoeconomic analysis, diabetes self-care, pharmacist
involvement,cost-effectiveness analysis, cost of utilization, cost of illness, cost of
minimization and cost-benefit analysis. PubMed, Science Direct, Springer Link and
Medline searched for the relevant studies. These databases searched for full text articles
ranging from 2007 to 2017. We tried to limit the search with the inclusion of studies
having any sort of pharmacoeconomically relevant component.
Key Findings: Cost of illness varied among the countries in managing diabetes
mellitus, and the cost of managing diabetes complications were twice the cost of
management of diabetes. Continuous involvement of the pharmacist in primary health
care is a cost-effective strategy and pronounced to be essential for helping diabetes
patient in controlling and managing their disease. Implementation of diabetes self-care
by pharmacists such as lifestyle intervention rendered improved quality of life of patient
without any increase in health care cost. Self-care management generates intensive
blood glucose control and improved quality of life.
Conclusions: Implementation of diabetic self-care intervention including intensive
lifestyle intervention, education, self-monitoring of blood glucose and adherence toward
medication-initiated reduction in the overall healthcare cost of diabetic patients compared
to patients relying on only any one of the interventions. Impact of diabetes self-care
intervention by pharmacist reported to significantly reduce the HbA1C levels of diabetic
patients along with the reduction of yearly healthcare cost. This review showed that
pharmacist involvement in diabetes self-care interventions prove to be cost-effective
and can significantly affect the condition of the diabetic patients and reduces the risk
of complications.
Keywords: pharmacoeconomic analysis, diabetes self-care, pharmacist involvement, cost-effectiveness analysis,
cost of utilization, cost of illness, cost of minimization, cost of benefit
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INTRODUCTION
Diabetes, a metabolic disorder with rapid emerging epidemic,
accounts for a total of 387 million global population living
with diabetes till 2014 (1). It is associated with substantial
indisposition toward other illnesses and a major risk factor
for cardiovascular disease, stroke, and renal complications (1).
According to the National Health andMorbidity Survey (NHMS)
2011, “the prevalence of diabetes in Malaysia had amplified
relatively from 15.2% (2011) to current 17.5%, compared to the
relative increase of 31.0% between 2006 (prevalence: 11.6%) and
2011” (2). Diabetes cases also increase sequentially with age and
are at its peak in the age group of 70–74 years (2). The intensifying
drift in diabetes is distressing because the disease generates
undesirable impacts on patients, their families and caregivers and
society, both humanistically and financially owing to significant
cost involved in diabetes care (1).
Diabetic patients generally handle their daily activities
independently (3). Self-care management is important to halt
the progression of diabetes and its complications as the goal of
treatment is simply to prevent microvascular and macrovascular
complications (4, 5). However, this proves to be difficult as the
key to effective management lies in consistent cooperation of the
patient. Generally, complications of diabetes manifest when there
is inappropriate compliance to self-care recommendations which
stems from poor self-discipline and education followed by lack of
support from family members (6). Thus, it is important for the
patients to realize that their self-confidence and self-discipline
promote better self-care and overall improved health outcomes
(7, 8). Self-care components comprises of self-monitoring of
blood glucose (SMBG), diet control, optimum physical exercise,
adherence to medication/s and proper foot and eye care (6).
Self-monitoring of blood glucose (SMBG) means that the
initiative to regularly check and record blood glucose through
glucometermust be with the patient. This continuousmonitoring
is expected to alert the patient of any discrepancies in the level
and prompt to take appropriate measures. However, this vital
component of self-care is generally missing in diabetic patients
(6). In this Ethiopian study nearly half of study subjects checked
their blood glucose level only during follow up visits (every 3–
4 months) or when they feel ill (6). This emphasizes that the
understanding and motivation of patients about SMBG is crucial
and the patient needs to be highly motivated for regular checking
of blood glucose. The mere act of blood glucose monitoring will
be insignificant if the patient is not motivated to implement it on
a regular basis and unable to comprehend the correct measure of
self-checking (9, 10).
Adherence to dietary control and diet patterns are significant
parameters in improving diabetes control. According to Tol
et al. (3) diet control adherence and exercise are significantly
associated with glycemic control. Among the self-care practices,
dietary control was considered the most essential component as
majority avoid ingestion of table sugars, sweet drink and foods
(6). Contrary to diet control, physical exercise showed a negative
result. The statistics from National Health and Morbidity Survey
in 2015 showed that the level of physical activity gradually
decreased with increasing age and apparently seen mostly in
elderly. Lack of motivation, lack of interest, busy work schedule
and patients’ perspectives and lack of awareness regarding
the benefits of exercise in diabetes seem to be implicated in
neglecting proper self-care (6).
Self-care component of adherence toward medication can be
defined as the proportion of medication taken and also defined
as the average change of the amount of missed medication
within the last seven days (11). Adherence to medication is
important because it is one of the ways to prevent any possible
complications in diabetic patients (12). In a systematic review
of randomized controlled trials, significant changes in blood
pressure and blood glucose levels were found in the intervention
groups receiving pharmaceutical care in the study. Pharmacist
also plays an important role in this self-care component as the
involvement of a pharmacist contributes to an improvement of
knowledge and self-care activities (11).
A major cause of morbidity and disability for people with
diabetes are foot ulcers and amputations. It is important for
having early recognition and management of independent risk
factors for ulcers and amputations as it can prevent or delay the
onset of adverse outcomes. There were few recommendations
that has been suggested by Mayfield and colleagues (13). People
with evidence of increased plantar pressure, such as erythema,
warmth, and callus, should use footwear that cushions and
redistributes the pressure. Other than that, people who are with
extreme bony deformities that cannot be accommodated with
the commercial therapeutic footwear, may need custom-molded
shoes.
OBJECTIVE
To review the involvement of pharmacists in diabetes self-care
from an economic perspective.
Method
A literature search was performed from September 2017 to
November 2017 to identify published studies related to the
analysis of the involvement of pharmacists in diabetic self-care.
Any study related to the economical perspective was included in
the review. PubMed, Science Direct, Springer Link and Medline
were used to search and retrieve the articles. The terms and
keywords applied were “pharmacist involvement,” “diabetic self-
care,” “cost-effectiveness,” “cost-minimization,” “cost-utilization,”
“cost-benefit,” “cost-illness” and combinations of these terms.We
reviewed the evidence from different types of studies such as
meta-analysis study, systematic review, longitudinal qualitative
study, descriptive cross-sectional study and randomized control
trial. The search was limited to articles published in English
within 12 years’ time frame; i.e., between 2005 and 2017.
Overall, a total of 4 articles were retrieved which encompass the
contribution of pharmacists from the economical perspective.
Cost Effectiveness Analysis
A 66-month program called The Patient, Pharmacists
Partnership (P3 Program) by Rodriguez de Bittner et al.
(14) controlled the effectiveness regarding clinical outcome
and cost saving of continuous pharmacist-delivered services in
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employed diabetic patients over 5 years period. Six self-insured
employers offered this program to their employees and family
members with type 1 or types two diabetes for 3.5 years.
The effectiveness of this program regarding clinical outcome
evaluated using percent changes in laboratory measures from
baseline to the latest and recent follow up-value; where the
primary clinical outcome changes were in HbA1c value while
secondary clinical outcome changes were in LDL, systolic blood
pressure (SBP) and diastolic blood pressure (DBP). For economic
outcomes, the patients’ cumulative medical, pharmacy, and total
costs, including copayments, were compared for the 12 months
before and after their baseline measures (14).
A significant decrease in HbA1c value within 6 months after
the initiation of the program observed in patients whom initial
value was out of standard range. The same goes with LDL value,
SBP value and DBP value which showed significant decrease
within 12 months in patients with out-of-range value initially.
The effect of P3 Program toward therapeutic goal decreases over
time which may be due to the patients become less sensitive to
engage with the program over a period. However, this may be due
to patient became overconfident in managing their diabetes alone
leading to their gradual decrease in participation of the program
(14).
Regarding economic outcome, the average per-patient all-
cause medical care costs significantly declined by $1321 (26%,
P < 0.001) and the decrease contributed a 33% decline in
emergency department visits and hospital admissions in the year
following enrolment in the program. Meanwhile, the reduction
in all-cause medical care cost came together with an increase
of $603 (17%, P ¼ 0.20) in prescription drug costs per patient
per year to the employer. The difference between these two
costs lead to the saving which averaged around $717 (8.3%) per
patient per year in total annual health care costs to employers
(P ¼ 0.32), unadjusted for changes in copayments for diabetes-
related medications and supplies averaging $309 per patient;
although waived for the patient but paid by the employer in
the second year. After subtracting this figure from employer’s
estimated post-year pharmacy cost, annual prescription drug
costs increased by $295 (8%, P ¼ 0.52) per patient, resulting in
total annual health care costs decline of $1031 (12%, P ¼ 0.15)
per patient (14).
In a study conducted by Simpson et al. (15), the authors
concluded that adding pharmacists in primary healthcare
to decrease cardiovascular risk in type 2 diabetes mellitus
is a cost-effective strategy. During the 1-year program in
five Canadian primary care clinics, 260 patients with type
2 diabetes mellitus were divided into a control group and
intervention group. The intervention group had sessions
with the pharmacist, who conducted medication history
and physical examination and any issues with medication
management recommended to be addressed with the patients
during the follow-up session. Meanwhile, the control group
received usual care without any intervention from the
pharmacist. After one year, all patients were seen face to
face to determine the effectiveness of the program (15). The
primary outcome was a decrease in ≥10% in systolic blood
pressure, while the secondary outcome was a reduction in
10-year cardiovascular risk using the UK Prospective Diabetes
(UKPDS) Risk Engine. For cost-effectiveness analysis, the
intervention considered cost-effective if; (1) it costs less (negative
incremental cost) and more effective (positive incremental
health effect); or (2) it cost more but more useful than
comparator and society is willing to pay for the additional cost
(15).
The result shows that the mean annual cost for the
pharmacist intervention was estimated to be $226 (±$143)
per patient. There was an overall cost saving of $190 for
the intervention group, but the difference with the control
group was statistically insignificant (95% CI –$1040, $668).
The cost-effectiveness analysis shows that the pharmacist
intervention is dominant compared to control group because
it costs less (–$190) and more effective accounting for 66%
of 10,000 bootstrap replications (15). When a societal cost-
effectiveness threshold (society’s willingness to pay for a
reduction of 1% in cardiovascular risk) of $31,500 considered,
the probability that the intervention would be cost-effective
was 99%. Conclusively, a pharmacist intervention is cost-
effective for reducing cardiovascular risks in type 2 the patients
(15).
The research from Taylor and associates (16) on the economic
evaluation of a community pharmacy-delivered disease state
management (DSM) service for type 2 mainly focussed on
developing, implementing, and evaluating a standardized disease
state management program for diabetes in community pharmacy
to boost and enhance patient health and lower health care
costs. Taylor et al. (16) offered and executed specialized
care for type 2 diabetes in DSM project as compared to
standard care regarding the point of view of the healthcare
sector. There were an intervention and control groups. The
intervention group provided with the specialized service that
included one initial visit with six follow-up visits, all of
which took place over approximately 9 months whereas the
control group was assessed at baseline and then again at 9
months only. The intervention group enjoyed the privileges
such as being instructed about blood glucose monitoring and
were provided with Medisense blood glucose monitors and
a medication review by a trained pharmacist if the patient
had issues related to their medications (16). Patients also
advised about their lifestyle and self-care, and the downloaded
blood glucose monitoring data were printed out and discussed
at each visit. For the control group, during that 9-month
period, patients received no further intervention but only the
standard care they usually received. It was observed that for
the intervention group, the total cost of providing specialized
services including pharmacist time, medication review, prints
out, phone calls with diabetes-related healthcare such as
medicine costs and resources used was $A1821.12 per patient.
On the other hand, for control group which did not have
any specialized services but with only standard services of
medications, the total cost was lower with value of $A1437.81 per
patient (16).
Also, for the effectiveness, it was noted that the HbA1c levels
were decreased by 0.46% from baseline for the intervention group
whereas for the control group a reduction of only 0.03% was
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marked. Moreover, an outstanding decrease on participants with
elevated HbA1c at follow-up in the intervention group, which
seemingly not achieved in the control group. To get a 0.43%
reduction in the HbA1c achieved by the specialized services, the
cost calculated is $A383 per patient per 9 months (16).
Cost Benefit Analysis
Cost-benefit analysis (CBA) in type 2 diabetes mellitus self-care
management notably observed in Australia and Malaysia. The
Malaysian study aimed to analyze the CBA for the program
named diabetes self-management program, DSMP in short, by
utilizing the payment card contingent valuation (CV) method
(17). The Australian study known as SugarCare program only
involved community pharmacies in three regions of New South
Wales (18). The study aimed to collect evidence concerning the
benefit of the optimized diabetes care given by the community
pharmacies in comparison to the standard care, regarding patient
preference and CBA (18). SugarCare compared the control
and intervention groups concerning the overall diabetes care,
information about medicines, diet and exercise, discussion about
medications, diabetes, and blood glucose, measurement of blood
glucose, management of medications or disease problems and
encouragement and support to change lifestyles. Duration of
this program was about 9 months. After that, the consent was
obtained to recruit the SugarCare patients for the consumer
preference survey and CBA study by using a payment card to
assess the maximumWTP (18). The consumer preference survey
consisted of satisfaction and preference surveys. The response
on the satisfaction survey of each SugarCare component was
recorded using the Likert scale of 1–5 scale, whereby 1 indicated
for “not very satisfied” and five was for maximum satisfaction.
The participants of the preference survey were asked to choose
between the scenario in control group (Scenario A-standard care)
and the situation in intervention group (Scenario B-enhanced
care).
Additionally, the WTP scores stated on the payment card
were AUD3.50, AUD10, AUD30, AUD60, and patient preference
amount ofWTP. The intervention group had to attend six follow-
ups to the participating community pharmacies apart from the
first and the final visits. On the contrary, the patients in the
control group only participated in the first and last visits. At
the beginning and end of the program, the HbA1c, lipids, blood
pressure and BMI of the respondents recorded. Initially, 239
patients enlisted into SugarCare. However, only 143 qualified
patients joined SugarCare. Upon the completion of the program,
78 participants gave the consent to involve in the CBA study,
with only 75 respondents successfully finished the survey (18).
Forty-five patients of the intervention group and 30 patients of
control group significantly satisfied with SugarCare components
namely information about diet and exercise, measurement of
blood glucose, management of medications or diabetic problems,
discussion of diabetes and blood sugar and encouragement and
support to change lifestyles. Generally, 44 patients preferred
Scenario B than Scenario A, though this finding was insignificant
(18). The WTP for Scenario A was AUD3.50 whereas WTP of
Scenario B amounted to AUD10 (18).
DISCUSSION
In the current review all the included interventional studies (14–
16, 18) reflected that pharmacist patient program or collaboration
had good economic outcomes and also advocated improved
health outcomes in the long term. A positive noted was also
observed for WTP values for their favored care.
The study Taylor et al. (16) found out that HbA1c levels
decreased by 0.46% in the intervention group compared with a
change of 0.03% in the control group after 9 months. Moreover,
the study also mentioned that the yearly costs for intervention
for each patient is calculated with $A383 in the first 9 months
and it is probable to positively affect in a saving the healthcare
system long term. Similarly, study by Rodriguez et al. (14) showed
that within the period of 6 months of the P3 program, there
was an impressive decrease in HbA1c value of the participant
and the sum of the yearly health care costs to employers was
found to lessen by $1031 per beneficiary. With reference to both
studies (14, 16), Hb1Ac can be used as a marker to prove the
effectiveness of diabetes disease program management as several
studies has shown that sustaining HbA1c level below 7% leads to
lowering of risk of complications of diabetes and diabetes-related
death. Moreover, in an economic analysis done by (15) proposed
that the involvement of pharmacists is considered cost effective
measure for reducing cardiovascular risk in patients with Type 2
diabetes.
From the studies done, it can be deducted that there is mark
reduction in the Hb1Ac reading with the involvement of the
pharmacist. Therefore, based from our analysis it can be said
pharmacist intervention in the diabetes self-care can be regarded
as cost effective. Generally, there are some limitation from the
studies above which is the study are only restricted to a 1-year
time thus it can affect the long-term cost-effectiveness of adding
pharmacists to primary care teams. Secondly, health utilization
information was obtained from patient self-report, which may
influence the reliability. Thirdly, in the study the participant are
varied in term of mean Hb1Ac levels at baseline therefore it can
affect the final interpretation of reduction in Hb1Ac.
Both studies for CBA used WTP method via payment card
to measure benefit using the monetary value. WTP is used to
measure both indirect and intangible benefits. WTP is measured
by CV that includes hypothetical scenario and bidding vehicle.
DSMP and SugarCare studies employed bidding vehicle by
applying the payment card, only differed in the monetary unit.
DSMP used Ringgit Malaysia (RM) whereas SugarCare benefit
was measured by Australian dollars (AUD) of 2002 currency
value.
The study in USM, Malaysia included the involvement of
two pharmacists in its diabetes self-care program (17). The
pharmacists might contribute to the program via the components
namely the diabetes medications related problems and diabetic
foot care management. The patients might benefit from the
DSMP based on the life expectancy. It was believed that the
program could extend about 5 years of the life span of being
diabetic. In contrast, DSMP might elicit the life span of the
diabetic patient for 7.5 years because it was expected that the
diabetic patient might get ESRD at the age of 67.5 years old from
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the normal life expectancy of Malaysians, which is 75 years old
(17).
In comparison, the net benefit of DSMP to prevent one
case of ESRD among diabetic patients is greater than the net
benefit of this program in overall diabetic clinical course. Overall,
this program is economically beneficial because its benefit to
cost ratio was greater than one, though only by 0.2 point.
Significant higher WTP was observed among the richer, well-
educated and longer diabetic state patients. Richer respondents
might want to pay more for the program if they appreciated
the benefits they would get from DSMP. Higher education
patients might acknowledge the severity of diabetes mellitus
complications and eager to prevent them from happening. Lastly,
the diabetic patients that had been in diseased state for longer
period probably were highly motivated to get better health after
their participations in DSMP thus they wanted to spend at higher
cost if DSMP would be continued in the future (17).
Conversely, SugarCare program focused on the engagement
of community pharmacists in the diabetes care. Several eligible
SugarCare patients withdrawn themselves from the consumer
preference and WTP surveys, with 17 of them stated their
reasons of study withdrawal. About 19 respondents favored
SugarCare similarly with the visit to the diabetes specialist
with significant value of 0.005 (18). There is insignificant
difference in total satisfaction between the standard diabetes
care and enhanced diabetes care. In contrast, Intervention
group had shown prominent satisfaction in individual SugarCare
component namely the management of diabetes medications and
diabetes issues.
Meanwhile, overall WTP values, measured by median
maximum WTP value was remarkably greater for Scenario
B, which amounted to AUD10, as compared to AUD3.50 for
Scenario A with p-value of < 0.03 based on the patients’ care
preference. However, the difference between the Intervention
groups and the Control groups was not noticeable regarding this
matter, since both of the groups could rate for either scenario.
It was found that the WTP values were affected by the patients’
income but this finding cannot be evaluated further due to
the limited sample size in this study. The patients wanted to
pay higher for Scenario B or optimized care because of the
comprehensive care that was given by the pharmacists in those
six follow-ups. Ironically, the Intervention and Control group
could not be differentiated since there is possibility of having bias.
For instance, most of the respondents in the Intervention group
would opt to Scenario B because they had experienced the care
provided and vice versa.
There were some weaknesses and limitations in the previous
studies. The first study did not assess the CBA in more life-
threatening complications such as diabetic ketoacidosis and
hyperosmolar hyperglycemic nonketotic syndrome (HHNS).
Moreover, the recruitment of the patients was difficult to be
conducted. Inadequate study sample was observed because and
most of the results obtained were derived from assumptions
only. In addition, it was tricky to evaluate the exact number of
complications that could be avoided owing to this program. The
second study proposed the future study to take account of the
incremental benefit assessment that is easily to be comprehended
by the study subjects. The limitations detected were inadequate
sample size and presence of bias in conducting that study.
Limited sample sizemade the CBA study could not be generalized
to the Australian population.
LIMITATIONS OF THE STUDY
Several limitations identified in the previous studies. Firstly,
a small sample size of study subjects could not reflect other
populations outside the study settings. Small sample size
also might lead to inadequate data and therefore findings
are sometimes not generalized. The researchers might have
experience this limitation due to difficulty in recruiting the
participants. Other than that, biases also observed in previous
pharmacoeconomic analysis studies. These biases involved the
choice of selecting the respondents and preference of treatments
given to the patients. In CEA the participants required to self-
report some of the data which might lead to the inaccuracy of
data.
Besides, some of the studies included diabetes complications
in the pharmacoeconomic analysis of their respective diabetes
self-care programs. For instance, the CBA study was having
difficulty in measuring the exact number of complications other
than ESRD that could be prevented due to DSMP whereas the
CEA study only evaluated cardiovascular diseases secondary to
diabetes mellitus in one-year time. The cardiovascular diseases
are chronic conditions which may take a longer time to
progress. Due to the limited duration of the study, long-term
CEA involving pharmacists in primary care teams was unclear.
Therefore, the limitations mentioned beforehand contributed
to the limitations of this study. Furthermore, the literature on
diabetes self-care is in scarcity as compared to management
of diabetes mellitus. Also, most of the research on this matter
rarely involve pharmacists as a whole e and unlikely engagement
of pharmacists in diabetes self-care, the involvement of other
healthcare professionals and pharmaceutical companies well-
documented. CEA studies are well-documented than other
costs. Consequently, huge research gap between CEA and CUA
literatures is observed.
RECOMMENDATIONS
More future research should be directed to diabetes self-care
because diabetes mellitus is a chronic disease which needs
comprehensive management. Moreover, the involvement of
pharmacists in diabetes self-care should be emphasized in future.
Other costs such as COI, CMA, and CUA should also be
the focus of pharmacoeconomic analysis rather than CEA to
ensure adequate data in correlating cost and benefit of diabetes
self-care.
CONCLUSION
The overall costs of managing diabetic patients present with
complication are more than twice compared to those without
complications. The direct cost of illness can be reduced by
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implementation of diabetic self-care intervention including
intensive lifestyle intervention, education, self-monitoring of
blood glucose and adherence to medicines. Implementation of
more than one self-care intervention found to reduce the overall
healthcare cost of diabetic patients compared to patients relying
on only one of the latter components. Impact of diabetic self-
care intervention by pharmacist found to significantly reduce
HbA1C levels of diabetic patients along with reduction of
yearly healthcare cost by $1031 per beneficiary showing the
effectiveness of intervention. Pharmaceutical care intervention
with involvement of pharmacists proven to further improve in
patient’s quality of life with the spending cost of $88,600 per
QALYs gained compared to higher cost in usual care. This review
paper showed that pharmacist involvement in diabetic self-care
interventions are proven to be cost effective and can significantly
affect condition of the diabetic patients and reduce the risk
of complications.
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